SNaPP Trial goes live

Congratulations to the SNaPP Trial team who started recruitment of their MRFF funded study this July, enrolling 5 participants already at the lead site, The Royal Melbourne Hospital, in their first week.

SNaPP (Sugammadex, Neostigmine, and Postoperative Pulmonary Complications ) is a multi-centre, patient-and observer-blinded randomised controlled trial of sugammadex or neostigmine to reverse neuromuscular blockade in adult patients having abdominal and thoracic surgery under general anaesthesia.

Congratulations to the SNaPP Trial team in particular Chief Principal Investigator Prof. Kate Leslie AO, Trial Manager Sofia Sidiropoulos, and Clinical Trial Coordinator Bhavita Patel, who have all worked hard on preparing for launch, including finalising the CRF.

Research Path is a specialist at providing customised and novel tools to integrate with our feature-rich Clinical Trial Management System. If off the shelf won’t do, get in touch to see how we can support you -

Return to News